116 related articles for article (PubMed ID: 35819571)
1. ASO Author Reflections: Inheritance of Adrenal Permissive HSD3B1 Genotype Negatively Impacts Outcomes in Hormone Receptor-Positive Postmenopausal Breast Cancer.
Flanagan MR; Sharifi N; Gadi VK
Ann Surg Oncol; 2022 Oct; 29(11):7202-7203. PubMed ID: 35819571
[No Abstract] [Full Text] [Related]
2. Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer.
Flanagan MR; Doody DR; Voutsinas J; Wu Q; Banda K; Sharifi N; Li CI; Gadi VK
Ann Surg Oncol; 2022 Oct; 29(11):7194-7201. PubMed ID: 35776258
[TBL] [Abstract][Full Text] [Related]
3. Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer.
Kruse ML; Patel M; McManus J; Chung YM; Li X; Wei W; Bazeley PS; Nakamura F; Hardaway A; Downs E; Chandarlapaty S; Thomas M; Moore HC; Budd GT; Tang WHW; Hazen SL; Bernstein A; Nik-Zainal S; Abraham J; Sharifi N
JCI Insight; 2021 Oct; 6(20):. PubMed ID: 34520399
[TBL] [Abstract][Full Text] [Related]
4. Association Between Adrenal-Restrictive HSD3B1 Inheritance and Hormone-Independent Subtypes of Endometrial and Breast Cancer.
McManus JM; Vargas R; Bazeley PS; Schumacher FR; Sharifi N
JNCI Cancer Spectr; 2022 Sep; 6(5):. PubMed ID: 35947687
[TBL] [Abstract][Full Text] [Related]
5. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Hearn JWD; Sweeney CJ; Almassi N; Reichard CA; Reddy CA; Li H; Hobbs B; Jarrard DF; Chen YH; Dreicer R; Garcia JA; Carducci MA; DiPaola RS; Sharifi N
JAMA Oncol; 2020 Apr; 6(4):e196496. PubMed ID: 32053149
[TBL] [Abstract][Full Text] [Related]
6. Expression of 3β-Hydroxysteroid Dehydrogenase Type 1 in Breast Cancer is Associated with Poor Prognosis Independent of Estrogen Receptor Status.
Chang YC; Chen CK; Chen MJ; Lin JC; Lin CH; Huang WC; Cheng SP; Chen SN; Liu CL
Ann Surg Oncol; 2017 Dec; 24(13):4033-4041. PubMed ID: 28744792
[TBL] [Abstract][Full Text] [Related]
7. ASO Author Reflections: Can Genomic Recurrence Score Replace SLNB in Postmenopausal Women with ER+/HER2- Breast Cancer?
Amlicke MJ; Spanheimer PM
Ann Surg Oncol; 2022 Nov; 29(12):7670-7671. PubMed ID: 35831528
[No Abstract] [Full Text] [Related]
8. HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond.
Sabharwal N; Sharifi N
Endocrinology; 2019 Sep; 160(9):2180-2188. PubMed ID: 31271415
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer.
Shiota M; Fujimoto N; Sekino Y; Tsukahara S; Nagakawa S; Takamatsu D; Abe T; Kinoshita F; Ueda S; Ushijima M; Matsumoto T; Kashiwagi E; Inokuchi J; Uchiumi T; Oda Y; Eto M
Andrologia; 2022 Feb; 54(1):e14307. PubMed ID: 34747051
[TBL] [Abstract][Full Text] [Related]
10. Adrenal-Permissive HSD3B1 Genotype-An Invisible Stimulator of Prostate Cancer Mortality.
Schiffer L; Sharifi N
JAMA Netw Open; 2024 Mar; 7(3):e243402. PubMed ID: 38506812
[No Abstract] [Full Text] [Related]
11. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.
Hettel D; Sharifi N
Nat Rev Urol; 2018 Mar; 15(3):191-196. PubMed ID: 29231195
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of 3β-Hydroxysteroid Dehydrogenase Type 1 Suppresses Interleukin-6 in Breast Cancer.
Chang YC; Lin CH; Lin JC; Cheng SP; Chen SN; Liu CL
J Surg Res; 2019 Sep; 241():8-14. PubMed ID: 31004874
[TBL] [Abstract][Full Text] [Related]
13. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
14. Correlates of obesity in postmenopausal women with breast cancer: comparison of genetic, demographic, disease-related, life history and dietary factors.
Wasserman L; Flatt SW; Natarajan L; Laughlin G; Matusalem M; Faerber S; Rock CL; Barrett-Connor E; Pierce JP
Int J Obes Relat Metab Disord; 2004 Jan; 28(1):49-56. PubMed ID: 14557830
[TBL] [Abstract][Full Text] [Related]
15. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
Lu C; Terbuch A; Dolling D; Yu J; Wang H; Chen Y; Fountain J; Bertan C; Sharp A; Carreira S; Isaacs WB; Antonarakis ES; De Bono JS; Luo J
Ann Oncol; 2020 Sep; 31(9):1178-1185. PubMed ID: 32387417
[TBL] [Abstract][Full Text] [Related]
16. AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
Hettel D; Zhang A; Alyamani M; Berk M; Sharifi N
Endocrinology; 2018 Aug; 159(8):2884-2890. PubMed ID: 29850791
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study.
Andersen SW; Trentham-Dietz A; Figueroa JD; Titus LJ; Cai Q; Long J; Hampton JM; Egan KM; Newcomb PA
Menopause; 2013 Mar; 20(3):354-8. PubMed ID: 23435034
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
Breast Cancer Res Treat; 2010 Apr; 120(3):727-36. PubMed ID: 19672706
[TBL] [Abstract][Full Text] [Related]
19. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk.
Quick SK; Shields PG; Nie J; Platek ME; McCann SE; Hutson AD; Trevisan M; Vito D; Modali R; Lehman TA; Seddon M; Edge SB; Marian C; Muti P; Freudenheim JL
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1082-7. PubMed ID: 18483329
[TBL] [Abstract][Full Text] [Related]
20. The influence of the genetic variant within miRNA-binding site in estrogen receptor alpha gene on the risk of breast cancer in postmenopausal women on hormone replacement therapy.
Cerne JZ; Gersak K; Novakovic S
Cancer Biomark; 2010-2011; 8(3):123-8. PubMed ID: 22012767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
